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Nicotine and Biochanin A, but Not Cigarette Smoke,
Induce Anti-Inflammatory Effects on Keratinocytes
and Endothelial Cells in Patients with Behc¸et’s
Disease
Aylin Kalayciyan1,2, Helmut Orawa3, Sabine Fimmel1, Frank H. Perschel4, Jose´-B. Gonza´lez4,
Rudolf G. Fitzner4, Constantin E. Orfanos1 and Christos C. Zouboulis1,5
During periods of smoking, patients with Behc¸et’s disease have less oral aphthae than in abstinence. To
elucidate this observation, human keratinocytes and dermal microvascular endothelial cells (HMEC-1) were
incubated with serum of 20 patients with Behc¸et’s disease and 20 healthy controls for 4 hours. Maximum non-
toxic concentrations were determined and the cells were further treated with 6 mM nicotine, 3.3% cigarette
smoke extract (CES), 100 mM biochanin A, and 6.25/12.5 mM pyrrolidine dithiocarbamate alone and in
combinations for 24 hours. Serum IL-8 levels of patients were significantly lower than those of controls.
However, after 4 hours incubation with patients’ sera, IL-8 release by both cell types was markedly increased
when compared with the corresponding serum levels. The levels of IL-6 and vascular endothelial growth factor
(VEGF) release were after 4 hours similar with the corresponding levels in serum. IL-1 was not detected. Nicotine
significantly decreased IL-8 and -6 release by HMEC-1 maintained in both patients’ and controls’ sera, but only
IL-6 release by keratinocytes maintained in patients’ sera. VEGF release by both cells was markedly increased
after nicotine treatment in either serum. CES significantly decreased IL-8 release and increased production of
VEGF in keratinocytes maintained in patients’ serum. The phytoestrogen biochanin A alone and in combination
with nicotine further decreased the secretion of IL-8, -6, and VEGF in all experimental settings. Our data support
a specific anti-inflammatory effect of nicotine on keratinocytes and endothelial cells maintained in the serum of
patients with Behc¸et’s disease. Moreover, biochanin A is likely to exhibit similar and even more profound
results than nicotine.
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INTRODUCTION
Behc¸et’s disease (BD) is a complex of signs and symptoms,
with oral aphthae as a sine qua non-finding. Smokers have
been reported to exhibit less frequently oral aphthae than
non-smokers (Rizvi and McGrath, 2001; Kaklamani et al.,
2003). Moreover, we and others have observed that during
periods of smoking, patients with BD had less oral aphthae
(both in number and frequency) when compared to periods of
abstinence (Soy et al., 2000). A similar observation was made
in patients with recurrent oral aphthous stomatitis (unpub-
lished observations), whereas the disorder is overall present
in higher rates in non-smokers than in smokers (Tuzun et al.,
2000; Atkin et al., 2002; Rivera-Hidalgo et al., 2004).
Interestingly, higher levels of cotinine, a smoking derivative
with a long half-life in the circulation, was found in plasma of
a smoker control population than in smoker patients with
recurrent oral aphthous stomatitis (Atkin et al., 2002).
Best known among thousands of active materials in
tobacco is nicotine ([]-1-methyl-2-[3-pyridyl] pyrrolidine).
Recently, nicotine treatment has been the focus of interest in
ulcerative colitis, a disease of inflammation and ulcers in the
gastrointestinal mucosa (Pullan et al., 1994; Thomas et al.,
1995; Sandborn et al., 1997). However, the exact mechanism
of action of nicotine in ulcerative colitis remains unclear. On
the other hand, tobacco suppresses both humoral and cellular
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immunity (Miller et al., 1982; Holt, 1987). In previous in vitro
and in vivo studies, nicotine decreased the levels of IL-1b,
IL-2, IL-8, IL-10, and tumor necrosis factor-a (TNF-a) in
circulating mononuclear cells (Madretsma et al., 1996a, b;
Bhatti and Hodgson, 1997). In a study by Srivastava et al.
(1989), nicotine was shown to inhibit the formation of free
oxygen radicals in neutrophils. Thus, it is likely that nicotine
could suppress neutrophil-mediated inflammatory actions.
In an investigation conducted by Ouyang et al. (2000),
cigarette smoke constituents were demonstrated to be potent
inhibitors of IL-1b, IL-2, TNF-a, and IFN-g production by
peripheral blood mononuclear cells. Thus, in our study,
effects of nicotine and cigarette smoke extracts (CSE) on
cytokine release from keratinocytes and endothelial cells
maintained in the serum from patients with BD were
investigated.
RESULTS
Cell viability under treatment with nicotine, CSE, biochanin A,
and pyrrolidine dithiocarbamate
Cell viability under treatment with nicotine, CSE, biochanin
A, and pyrrolidine dithiocarbamate (PDTC) for 24 hours was
not affected by concentrations up to 6 mM nicotine, 3.33%
CSE, 100mM biochanin A, and 6.25 mM (for human dermal
microvascular endothelial cell (HMEC-1) endothelial cells)
and 12.5mM (for keratinocytes) PDTC. At higher concentra-
tions, increased rates of dead cells were detected, whereas
CSE exhibited a dose-dependent toxicity on keratinocytes and
HMEC-1 endothelial cells at concentrations X10%.
Serum cytokine levels
IL-8 levels in serum of BD patients were lower than those in
serum of healthy controls (median IL-8 levels: in keratinocyte
experiments 43.1 pg/dl in BD patients’ serum (interquartile
range 25.6 pg/ml) and 113.5 pg/dl in healthy controls’
serum (interquartile range 13.4 pg/ml; Mann–Whitney test:
P¼0.003) (Figure 1a); in HMEC-1 endothelial cell experi-
ments 43.5 pg/dl in BD patients’ serum (interquartile range
20.6 pg/ml) and 112.4 pg/dl in healthy controls’ serum (inter-
quartile range 78.5 pg/ml; Mann–Whitney test: P¼0.002)
(Figure 1b)). Individual IL-8 levels of the 20 BD patients did
not correlate with any particular clinical sign.
The levels of IL-6 and vascular endothelial growth factor
(VEGF) in BD patients’ serum were similar with those in
healthy controls’ serum. IL-1b could be detected neither in
BD patients’ serum nor in healthy controls’ serum.
Cytokine release by keratinocytes and HMEC-1 endothelial cells
A marked IL-8 release by human keratinocytes after a 4-hour-
incubation with BD patients’ sera occurred (148-fold higher
supernatant levels than BD patients’ serum levels; Wilcoxon
test: Po0.0005; Figures 1a and 2a, Table S1). Incubation with
healthy controls’ sera for 4 hours induced a similar but much
less abundant increase of IL-8 release (6.5-fold higher levels
in keratinocyte supernatants than in controls’ sera; paired
t-test: P¼ 0.01). The difference of the increase of IL-8 release
by keratinocytes induced by the BD patients’ sera and
the healthy controls’ sera was highly significant (t-test:
Po0.0005).
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Figure 1. Serum cytokine levels in cell culture experiments. (a) Serum cytokine levels in cell culture experiments. All comparisons represent the results obtained
by comparing median cytokine levels in BD patients’ versus controls’ serum used in human keratinocyte experiments (groups) and were performed by the
Mann–Whitney test. IL-6, no difference; IL-8, lower levels in patients’ serum, P¼0.003, VEGF, no difference. Stars indicate an extreme value. (b) Serum cytokine
levels in HMEC-1 endothelial cells experiments. All comparisons represent the results obtained by comparing median cytokine levels in BD patients’ versus
controls’ serum used in HMEC-1 endothelial cells experiments (groups) and were performed by the Mann–Whitney test. IL-6, no difference; IL-8 lower levels in
patients’ serum, P¼0.002; VEGF, no difference. Stars indicate an extreme value and circles an outlier.
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IL-8 was also released by HMEC-1 endothelial cells after a
4-hour-incubation with BD patients’ sera (6-fold higher levels
than the corresponding patients’ serum IL-8 levels; Wilcoxon
test: P¼ 0.001; Figures 1b and 2b, Table S1). In contrast, IL-8
release levels after incubation with healthy controls’ sera
were not significantly different than those in controls’ sera
(Wilcoxon test: P¼ 0.073). No difference of the increase of
IL-8 release levels by HMEC-1 induced by the BD patients’
sera and the healthy controls’ sera could be detected.
Although less pronounced than that of IL-8, IL-6 release
was observed in keratinocytes incubated for 4 hours with
patients’ sera (3.5-fold increase compared to the serum
levels; Wilcoxon test: P¼ 0.002; Figure 1a, Table S1). In
contrast, keratinocytes incubated with healthy controls’
sera did not release IL-6 (Wilcoxon test: P¼0.779 compared
with controls’ sera IL-6 levels). A trend for higher increase
of IL-6 release by keratinocytes incubated with patients’ sera
than with controls’ sera was observed (Mann–Whitney test:
P¼0.053; Figure 2a).
HMEC-1 endothelial cells released IL-6 after a 4-hour-
incubation with BD patients’ sera (5-fold higher levels
compared to the serum levels; Wilcoxon test: P¼0.002;
Figures 1b and 2b, Table S1) and after incubation with
healthy controls’ sera (Wilcoxon test: P¼0.03).
The keratinocyte supernatant levels of VEGF were lower
than serum levels after 4 hours incubation with both patients’
sera (3.5-fold decrease; Wilcoxon test: Po0.0005; Figures 1a
and 2a, Table S1) and healthy controls’ sera (Wilcoxon test:
P¼0.017). The levels of VEGF in keratinocyte supernatants
after 4 hours incubation with patients’ sera were higher than
those of cells incubated with controls’ sera (t-test: P¼0.006;
Figure 2a).
After a 4-hour incubation with BD patients’ sera, VEGF
levels in HMVC-1 endothelial cell supernatants were also
lower than the corresponding serum VEGF levels (4.5-fold
decrease; Wilcoxon test: Po0.0005; Figures 1b and 2b,
Table S1). The levels of VEGF in HMEC-1 endothelial cell
supernatants after a 4-hour incubation with patients’ sera
were higher than those of cells incubated with controls’ sera
(Mann–Whitney test: Po0.0005; Figure 2b).
Cytokine release after cell incubation with effectors and
inhibitors
The effects of the various 24-hour treatments of keratinocytes
and HMEC-1 endothelial cells with the effectors, the
inhibitors, and their combinations are shown in Figure 3.
IL-1 was not released in any experimental setting.
IL8 release by human keratinocytes. Nicotine did not affect
IL-8 release by keratinocytes in either patients’ or controls’
serum (Wilcoxon test) (Figure 3a, Table S2). CSE significantly
decreased IL-8 release by keratinocytes in BD patients’ serum
only (Wilcoxon test: P¼0.04). Biochanin A significantly
decreased IL-8 release by keratinocytes in patients’ serum
only (Wilcoxon test: P¼0.001). The inhibitory effect of
biochanin A on IL-8 release by keratinocytes was significantly
stronger than that of CSE in patients’ serum (Wilcoxon test:
P¼0.004) and in controls’ serum (Wilcoxon test: P¼0.012).
Biochanin A in combination with CSE had neither synergistic
nor antagonistic effect on IL-8 release in both groups
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Figure 2. Cytokine levels released by human cells in vitro. (a) Cytokine levels released by human keratinocytes after a 4-hour incubation with BD patients’ or
healthy controls’ serum. All comparisons represent the results obtained by comparing average cytokine levels released by human keratinocytes after 4 hours
incubation with BD patients’ serum with those after 4 hours incubation with controls’ serum (groups) and were performed by the t-test (exception: IL-6
Mann–Whitney test). For each cytokine, the average level after 4 hours incubation with BD patients’ serum was higher. IL-6, no significant difference, P¼ 0.053;
IL-8, Po0.0005; VEGF, P¼0.006. Circles indicate an outlier. (b) Cytokine levels released by HMEC-1 endothelial cells after 4 hours incubation with BD
patients’ or healthy controls’ serum. All comparisons represent the results obtained by comparing average cytokine levels released by HMEC-1 endothelial cells
after 4 hours incubation with BD patients’ serum with those after 4 hours incubation with controls’ serum (groups) and were performed by the Mann–Whitney
test. For each cytokine, the median level after 4 hours incubation with BD patients’ serum was higher. IL-6, no significant difference (P¼0.144); IL-8,
no significant difference (P¼0.754); VEGF, Po0.0005. Stars indicate an extreme value and circles an outlier.
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Figure 3. Cytokine/chemokine release by keratinocytes and HMEC-1 endothelial cells after incubation with effector and inhibitor compounds or their
combinations. (a) IL-8 release by keratinocytes; (b) IL-6 release by keratinocytes; (c) VEGF release by keratinocytes; (d) IL-8 release by HMEC-1 endothelial cells;
(e) IL-6 release by HMEC-1 endothelial cells; (f) VEGF release by HMEC-1 endothelial cells. All comparisons represent the results obtained by cells maintained
previously in patients’ serum and controls’ serum, respectively. Cytokine/chemokine release of the untreated cells after 24-hour incubation is compared with
each of the eight different cytokine/chemokine releases of treated cells after 24-hour incubation (exposures). The eight comparisons were performed by the
Wilcoxon’s test, unless otherwise identified (also see Table S2). Asterisks indicate an extreme value and closed circles an outlier.
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(in patients’ serum: reduction, Wilcoxon test: Po0.01;
in controls’ serum: no change, paired t-test); however,
in keratinocytes incubated in patients’ serum biochanin A
in combination with nicotine (in patients’ serum: reduction,
Wilcoxon test: Po0.01; in controls’ serum: reduction,
Wilcoxon test: Po0.05) exhibited a synergistic inhibitory
effect on IL-8 release compared with that of biochanin A
alone (Wilcoxon test: P¼ 0.025), PDTC, either alone (in
patients’ serum, Wilcoxon test; in controls’ serum, paired
t-test) or combined with CSE (in patients’ serum, Wilcoxon
test; in controls’ serum, paired t-test) or nicotine (in patients’
serum, paired t-test: in controls’ serum, Wilcoxon test), had
no effect on IL-8 release by keratinocytes.
IL-6 release by human keratinocytes. With respect to
medium alone nicotine significantly reduced IL-6 release by
keratinocytes in patients’ serum only (Wilcoxon test:
P¼0.015; in controls’ serum: no change, paired t-test)
(Figure 3b, Table S2). CSE had no effect on IL-6 release by
keratinocytes in either patients’ serum or controls’ serum
(Wilcoxon tests); however, keratinocytes treated with CSE
combined with PDTC released more IL-6 than keratinocytes
treated with PDTC alone (Wilcoxon test: experiments in
patients’ sera, P¼0.028; in controls’ sera, P¼0.021),
Biochanin A significantly decreased IL-6 release by keratino-
cytes in both patients’ and controls’ serum (Wilcoxon tests:
Po0.0005 and P¼0.012, respectively). Neither biochanin A
in combination with either nicotine (in patients’ serum,
Wilcoxon test; in controls’ serum, paired t-test) or CSE (in
patients’ serum, Wilcoxon test; in controls’ serum, paired
t-test) nor PDTC, either alone (in patients’ serum, paired t-test;
in controls’ serum, Wilcoxon test) or in combination with
nicotine (paired t-tests), had any effect on IL-6 release by
keratinocytes. Keratinocytes pretreated with patients’ sera
exhibited higher IL-6 levels following all nine different
exposure settings when compared with the cells pretreated
with controls’ sera (analysis of variance for repeated
measures; factor A: group; Po0.005).
VEGF release by human keratinocytes. Nicotine significantly
increased VEGF release from keratinocytes in both patients
and controls (Wilcoxon test: Po0.0005 and P¼0.012,
respectively) (Figure 3c, Table S2). PDTC did not affect the
inhibitory result obtained with nicotine on keratinocytes
maintained in patients’ serum, but counteracted the increas-
ing effect of nicotine on VEGF release on keratinocytes
maintained in controls’ serum (paired t-test: P¼0.028).
Biochanin A also counteracted the increasing effect of
nicotine on VEGF release on keratinocytes maintained in
patients’ and controls’ sera (paired t-test: Po0.005 and
Wilcoxon test: P¼0.012, respectively). CSE caused a slight
increase of VEGF release by keratinocytes pretreated with
patients’ sera (Wilcoxon test: P¼ 0.048) but had no effect on
cells maintained in controls’ sera (paired t-test). A significant
difference was assessed in the effects of nicotine in
comparison with CSE on keratinocytes maintained in both
patients’ and controls’ sera (Wilcoxon tests: P¼0.002 and
P¼0.036, respectively). PDTC, either alone (Wilcoxon test)
or combined with CSE (paired t-test), had no effect on VEGF
release from keratinocytes in patients’ serum, whereas in
controls’ serum, PDTC either alone (Wilcoxon test: Po0.05)
or combined with CSE significantly decreased VEGF release
(Wilcoxon test: P¼ 0.012). Although VEGF production by
keratinocytes was decreased under biochanin A treatment in
either set of sera, this effect was statistically significant only in
controls (Wilcoxon test: P¼0.025). The combined biochanin
A/CSE treatment did not affect VEGF release either in patients
or in controls conditions (Wilcoxon tests).
IL-8 release by HMEC-1 endothelial cells. Although the
behavior of HMEC-1 endothelial cells to the nine different
treatment settings was similar in BD patients’ and healthy
controls’ sera experiments, more pronounced changes were
observed in cells pretreated with patients’ sera. Nicotine
significantly reduced IL-8 release by HMEC-1 endothelial
cells maintained in both patients’ and controls’ sera
(Wilcoxon tests: P¼ 0.002 and P¼0.007, respectively)
(Figure 3d, Table S2). CSE did not affect IL-8 release by
HMEC-1 endothelial cells either in patients’ or in controls’
sera (in patients’ serum, Wilcoxon test; in controls’ serum,
paired t-test). The differences of the effects of nicotine and
CSE were statistically significant in both patients’ and
controls’ sera (Wilcoxon test: Po0.0005 and P¼0.001,
respectively). PDTC and the combination nicotine/PDTC
caused a 2-fold increase in IL-8 release by cells pretreated
with patients’ sera (Wilcoxon tests: Po0.01). In contrast, in
cells pretreated with controls’ sera, a decrease of IL-8 release
induced by the PDTC/nicotine combination was observed
(Wilcoxon test: Po0.05). The CSE/PDTC combination further
increased IL-8 release in both experimental groups (13-fold;
Wilcoxon test: Po0.01 each). Biochanin A alone signifi-
cantly decreased IL-8 release by HMEC-1 endothelial cells in
both patients’ and controls’ sera (Wilcoxon test; P¼0.002
and P¼ 0.006, respectively). Biochanin A in combination
with either nicotine or CSE caused a striking decrease in IL-8
release by HMEC-1 cells (2.5-fold each; Wilcoxon tests:
Po0.01). These findings were more pronounced in cells
pretreated with healthy controls’ sera.
IL-6 release by HMEC-1 endothelial cells. Nicotine caused a
17% decrease in IL-6 release by HMEC-1 endothelial cells in
both patients’ and controls’ sera (Wilcoxon test: Po0.0005
each) (Figure 3e, Table S2), This decrease was more
prominent in controls (Mann–Whitney test: P¼0.011).
However, when combined with PDTC, nicotine did not
exhibit any effect on IL-6 release (in patients’ serum, paired
t-test; in controls’ serum, Wilcoxon test). CSE increased IL-6
release by HMEC-1 cells in both patients’ and controls’ sera
(Wilcoxon test: P¼ 0.005 and P¼0.11, respectively). The
contrasting effects of nicotine and CSE was statistically
significant in both patients’ and controls’ sera experiments
(Wilcoxon test: Po0.0005 each), but was more prominent in
the controls’ sera experiments (Mann–Whitney test:
P¼0.014). Biochanin A significantly decreased IL-6 release
by, HMEC-1 endothelial cells in both patients’ and controls’
sera (Wilcoxon test: P¼ 0.002 and P¼0.009, respectively).
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Biochanin A in combination with either CSE or nicotine in
patients’ serum significantly decreased the basal secretion of
IL-6 in these cells by about 2-fold (Wilcoxon test: Po0.0005).
The decrease was 3-fold in cells pretreated with controls’ sera
(Wilcoxon test: Po0.0005).
VEGF release by HMEC-1 endothelial cells. HMEC-1 cells
pretreated with patients’ sera exhibited higher values of VEGF
release following all nine different treatment settings when
compared to the ones pretreated with controls’ sera (analysis
of variance for repeated measures; factor A: group: P¼0.001)
(Figure 3f, Table S2). VEGF release by HMEC-1 endothelial
cells was increased with nicotine treatment in either set of
sera (paired t-test: P¼0.001 each). This effect was signifi-
cantly more pronounced in patients’ sera than in controls’
sera experiments (t-test: P¼0.005). The addition of PDTC to
nicotine in patients’ serum did not change this finding
(Mann–Whitney test; Po0.0005). When combined with
biochanin A, the increasing effect of nicotine on VEGF
release by HMEC-1 endothelial cells was counteracted
(Wilcoxon test: Po0.0005 each). Compared to the medium,
nicotine coupled to biochanin A exhibited a decreasing effect
on VEGF release in controls’ sera experiments (Wilcoxon test:
Po0.0005). CSE presented no effect on VEGF release by
HMEC-1 endothelial cells in patients’ (Wilcoxon test) and in
controls’ sera (paired t-test). Biochanin A decreased VEGF
release in both groups (Wilcoxon test: Po0.0005 each). The
addition of CSE to biochanin A did not change this result
(paired t-test: Po0.0005 (patients’ sera) and P¼0.001
(controls’ sera)). PDTC alone had an inhibiting effect on
VEGF release in controls’ sera (Wilcoxon test: P¼0.016; in
patients’ serum: no change, paired t-test). PDTC combined
with CSE had also an increasing effect on VEGF release by
HMEC-1 cells in control’s sera (Wilcoxon test: Po0.01; in
patients’ serum: no change, Wilcoxon test).
DISCUSSION
The exact mechanisms of inflammatory changes occurring in
BD are yet to be elucidated. Previous studies have shown an
increase in inflammatory cytokines and chemokines secreted
by mononuclear phagocytes and neutrophils in patients with
BD, such as TNF-a, IL-1, IL-6, and IL-8 (Lee et al., 1993;
Sayinalp et al., 1996; Katsantonis et al., 2000).
IL-8 is a potent leukocyte chemotactic factor being
specific for neutrophils. Zouboulis et al. (2000) have reported
that in patients with BD, IL-8 was increased in serum during
active disease. Furthermore IL-8 was demonstrated to be
secreted by small vessel endothelial cells. Similarly, in this
study, although IL-8 serum levels were not higher in patients
than that in controls, IL-8 production from keratinocytes and
endothelial cells incubated with patients’ sera was markedly
high. This may shed light to the fact that mucocutaneous
lesions in BD are almost entirely dominated by neutrophils
(Vigneswaran and Rodu, 2002).
Plasma IL-8 levels are higher in smokers than in non-
smokers. Although Iho et al. (2003) reported that nicotine
stimulates neutrophils in the respiratory tract to produce IL-8
in both time- and concentration-dependent manner, Sugano
et al. (1998) have previously shown an anti-inflammatory
activity of nicotine and Frederiksson et al. (2002) have found
that IL-8 is depressed in neutrophils of smokers. Moreover,
nicotine was demonstrated to enhance the differentiation-
specific proteins and enhance keratinization of oral mucosal
and epidermal keratinocytes (Kwon et al., 1999). Mio et al.
(1997) attributed IL-8 production by bronchial epithelial cells
to the ingredients of cigarette smoke.
The contradictory effects of nicotine and CSE on IL-8
secretion by endothelial cells were confirmed in our study. In
contrast, in keratinocytes incubated with BD patients’ sera,
both nicotine and CSE decreased IL-8 release, whereas a
diverse effect was observed in cells pretreated with controls’
sera. This selective activity on ‘‘diseased’’ keratinocytes may
explain the beneficial effect of smoking on oral aphthae of
BD patients. Moreover, the inhibitory effect of nicotine on
IL-8 release by endothelial cells in our study may represent an
additional beneficial factor of smoking on oral aphthae in BD
(Soy et al., 2000; Tuzun et al., 2000; Rizvi and McGrath,
2001; Kaklamani et al., 2003). Iho et al. (2003) have
suggested that chronic activation of neutrophils by nicotine
may reduce the capacity of neutrophils to accomplish their
specific immune responses. In addition, a reduction of
neutrophil recruitment to sites of inflammation by intra-
venous IL-8 has been demonstrated previously (Hechtman
et al., 1991; Ley et al., 1993). Pabst et al. (1995) also
demonstrated that nicotine can inhibit neutrophil and
monocyte defensive functions through a decrease in cytokine
production. Thus, in diseases like BD, where neutrophils
dominate the inflammatory response, this effect of nicotine
may become beneficial. On the other hand, Wang et al.
(2000) have shown that CSE augmented IL-8 release by
cultured human endothelial cells in a dose- and time-
dependent manner. Our results were consistent with this
report. A similar contradictory effect of nicotine and CSE was
detected on IL-6 secretion by endothelial cells in our study.
IL-6 is also a proinflammatory cytokine and nicotine
decreased IL-6 release by both cell types studied.
The major regulator of IL-8 gene expression is NF-kB,
therefore, PDTC, known to inhibit NF-kB activation in several
biological systems and to promote apoptosis (Schreck et al.,
1992; Chinery et al., 1997), was administered to the cells.
PDTC, especially when combined with nicotine or CSE,
stimulated cytokine release from both cell types, an effect
also described previously (Hellmuth et al., 2002). In
agreement with this finding, Watanabe et al. (1999) have
demonstrated that PDTC exerted dual activity of pro-oxidant
and antioxidant type. Furthermore, biochanin A, which is a
methyl ester of the phytoestrogen genistein and an inhibitor
of protein tyrosine kinase, significantly decreased the basal
secretion of IL-8 in both cell types.
On the other hand, cigarette smoke is able to induce
cellular oxidative stress and the oxidation depends on the
concentrations of CSE (Carnevali et al., 2003). Cigarette
smoke has also been reported to alter VEGF maintenance of
pulmonary endothelial cells (Kashara et al., 2001). We have
observed a marked increase of VEGF release through
treatment of both cell types with nicotine and CSE. Nicotine
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was demonstrated to upregulate VEGF expression in en-
dothelial cells in concentrations found in the blood plasma
of habitual smokers (Conklin et al., 2002), namely
6.2–19 108 mol/l. Previous clinical studies on the effects
of smoking on VEGF expression have been inconsistent. A
study showed no difference in plasma VEGF levels between
smokers and non-smokers (Belgore et al., 2000). In another
study, however, the majority of the individuals with
detectable plasma VEGF levels were smokers (Wasada
et al., 1998). The mechanism by which nicotine upregulates
VEGF expression in endothelial cells is still unknown. It
seems likely that nicotine interacts with the acetylcholine
receptor (nAChR), which has been detected on endothelial
cells (Macklin et al., 1998) and on epithelial cells of the skin
(Kurzen and Schallreuter, 2004). Nicotine is a potent stimulus
for angiogenesis, an effect probably mediated by nAChR
(Heeschen et al., 2001), and stimulates endothelial cell
proliferation (Villablanca, 1998). On the other hand, chronic
stimulation of keratinocytes with nicotine alters the geneti-
cally determined program of the cell differentiation-depen-
dent expression of nAChR subunits (Arredondo et al., 2001).
By interfering with acetylcholine signaling in keratinocytes,
nicotine can alter the normal balance of cell growth and
differentiation, which accelerates squamatization and in-
creases the risk for malignant transformation (Kurzen and
Schallreuter, 2004; Arredondo et al., 2005).
The significant anti-inflammatory effect of biochanin A in
both cell types deserves a special reference, especially as a
more pronounced anti-inflammatory effect was obtained
through the combination of biochanin A with nicotine.
Therefore, biochanin A alone or in combination with nicotine
topically applied may constitute an interesting candidate
regimen for aphthae treatment.
In conclusion, we observed substantial inhibitory effects of
CSE and nicotine on IL-8 and to a lesser extent on IL-6 release
by human keratinocytes and HMEC-1 endothelial cells. These
findings may explain the beneficial effect of smoking in BD,
also because IL-8, and to some extent IL-6, are likely to
induce pivotal proinflammatory signals in this disease (Lee
et al., 1993). Nicotine may cause immunoregulation by
affecting chemokine/cytokine production. This study also
demonstrates the different behavior of cells in terms of
cytokine release when stimulated with BD patients’ sera
compared to those of healthy individuals. The in vitro
evidence of beneficial effects of nicotine in BD is funda-
mental to our ongoing clinical trial with nicotine transdermal
patches in BD. In addition, the detected beneficial effect of
biochanin A implicates this compound as a candidate for
future developments in aphthae treatment. The development
of topical nicotinic cholinergic receptor subtype-specific
agonists is likely to exhibit beneficial effects on skin and
mucosae without inducing systemic adverse effects.
MATERIALS AND METHODS
Patients
Twenty patients (seven female and 13 male) with BD of 37.3710.8
years of age (range 24–65 years) and healthy controls (endothelial cell
study: 21 subjects (11 female and 10 male) of 31.178.4 years of age
(range 22–52 years);keratinocyte study: eight subjects (five female and
three male) of 32.178.4 years of age (range 21–42 years)) were
included in the study. Age and gender distribution of the groups were
similar (Mann–Whitney test and w2 test, respectively). Diagnosis of BD
was based on the criteria of the International Study Group for Behc¸et’s
Disease (1990). The study was approved by the Ethics Committee of
the Charite´ Universitaetsmedizin Berlin, Campus Benjamin Franklin
and adhered to the declaration Helsinki Priniciples. Patients were
included after providing consent for the use of their serum samples.
Materials
Nicotine, PDTC, and biochanin A were obtained from Sigma
(Deisenhofen, Germany). PDTC, an inhibitor of NF-kB activation,
and biochanin A, the methyl ester of the phytoestrogen genistein, an
inhibitor of protein tyrosine kinase, were used as inhibitors (Wang
et al., 2000). A working stock solution of 10 mM biochanin A was
prepared in DMSO and used to prepare all other dilutions in
corresponding medium for cell treatment. PDTC was dissolved in
phosphate-buffered saline and pH was adjusted to 7.2 in order to
produce a 0.1 M stock solution.
The human IL-1b, IL-6, IL-8, and VEGF ELISA kits were purchased
from R&D Systems (Wiesbaden-Nordenstadt, Germany). Biochanin
A was dissolved in DMSO (Sigma) and PDTC was diluted with
phosphate-buffered saline (Biochrom, Berlin, Germany).
Cigarette smoke extract
CSE was prepared by a modification of the method developed by
Carp and Janoff (1978). The filters of two commercial cigarettes
(60 mm) with tar content of 8 mg and nicotine content of 0.7 mg
were removed before attachment. Twenty milliliter of appropriate
culture medium was placed in a glass flask with a side arm. The
cigarettes were mounted in a 500-ml pipette tip that penetrated the
hole in the stopper of the flask and extended down past the side arm
connected to a syringe and ended about halfway from the bottom of
the flask containing the medium. The cigarette was lit and puffs were
introduced into the flask over a period of 2–3 minutes by applying
mild suction. The smoke was released on to the surface of the buffer
without bubbling and allowed to dissolve in it for 1 minute with
gentle shaking. The resultant solution was filtered through a 0.22-mM
Millex-GS filter in order to remove large particles. This solution was
considered to be 100% CSE. It was diluted with medium to obtain
the desired concentration in each experiment and used within
30 minutes of preparation. This method for preparing CSE for in vitro
is widely used in respiratory research (Ishii et al., 2001). Before their
administration, CSE was diluted 30-fold with the cell culture
medium. CSM of the dilution was 2.94 measured by a spectro-
photometer at 320 nm (0.150 absorbance equals to 1 CSM).
Cell cultures
Human keratinocytes were isolated from normal neonatal foreskin
specimens, which were removed during circumcision. Circumcised
foreskin samples were kept in physiological saline at 41C. Cells were
isolated within 24 hours of surgery. Foreskin samples were washed
several times in phosphate-buffered saline. Subcutaneous tissue was
removed from the dermis with sterile surgical scissors. The
remaining tissue was placed in a bacterial culture plate and minced
into fine pieces, which were then incubated overnight in 10 ml of
0.25% trypsin at 41C and further at 371C for 2 hours. The epidermal
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layer was separated, washed, and then centrifuged. The cell pellet
was resuspended in keratinocyte growth medium (KGM) and
inoculated in a culture plate. KGM was formulated with keratinocyte
serum-free basal medium (GIBCO, Invitrogen, Berlin, Germany),
25 mg/ml bovine pituitary extract, 2.5 mg/ml human recombinant
epidermal growth factor, 100 U/ml penicillin, and 100 mg/ml
streptomycin (all Biochrom). The culture medium was changed
thrice weekly from 7 days after plating, when stable colonies
appeared. The keratinocytes were cultured until 80% confluence in
tissue culture flasks at 371C and 5% CO2. At the time of experiments
second- and third-passage cells were used.
Immortalized HMEC-1 (a gift from Dr T Lawley, Emory
University, Atlanta, GA) (Ades et al., 1992), shown to exhibit
characteristics and functions similar to those of human dermal
microvascular endothelial cells, were maintained in endothelial cell
growth medium (EBM; PromoCell, Heidelberg, Germany) supple-
mented with 2% fetal calf serum, 1 mg/ml hydrocortisone, 100 U/ml
penicillin, and 100 mg/ml streptomycin (all Biochrom) at 371C in an
atmosphere containing 5% CO2. Before proceeding to the in vitro
experiments, confluent HMEC-1 cells in 24-well plates (Biochrom)
were adapted for 3 days to EBM without additives and washed twice
with PBS without Ca2þ or Mg2þ .
Cultured cells were treated with the serum from each patient and
healthy control diluted 1:5 with KGM or EBM, respectively, and
incubated for 4 hours, which was found to be the optimal incubation
time for cytokine secretion in preliminary experiments. Cells only
incubated with medium served as controls. After 4 hours, the
supernatant was drawn for evaluation and the cells were further
incubated for 24 hours, in KGM or EBM, respectively, supplemented
with nicotine, CSE, PDTC, biochanin A, nicotine with PDTC, CSE
with PDTC, nicotine with biochanin A, and CSE with biochanin A.
Cells incubated with KGM or EBM, respectively, without additives
served as controls. At the end of incubation, supernatants were
harvested and aliquots were drawn for evaluation.
Cell viability
The effects of nicotine, CSE, and the inhibitors on cell viability were
evaluated by the lactate dehydrogenase assay (Cytotoxicity detection
kit; Roche, Mannheim, Germany). Human keratinocytes and HMEC-1
endothelial cells were seeded into 24-well culture trays
(4 104 cells/ml) and grown until confluent. The cells were rendered
quiescent for 24 hours in serum-free medium (KGM or EBM,
respectively) and then exposed to serial dilutions of effector and
inhibitor substances for 24 hours at 371C, 5% CO2. The culture
supernatants were then analyzed using a lactate dehydrogenase
assay kit, according to the manufacturer’s instructions. The optimum
concentration of all was determined according to the cytotoxicity
level of less than 5%.
Serum cytokine levels
Levels of IL-1a, IL-6, IL-8, and VEGF in serum samples were
measured using commercially available ELISAs (Quantikine ELISA-
kits; R&D Systems). Optical density was measured at 450 nm in a
Dynatech ELISA reader.
Statistical methods
Cytokine release was measured as a continuous outcome variable.
Specific cytokine release under contribution of patients’ or controls’
sera, called ‘‘groups’’, as well as under the influence of effectors,
inhibitors or combinations of those, called ‘‘exposures’’, was
assessed.
Approximately normally distributed continuous data were
numerically described by arithmetic means and standard deviation.
Not approximately normally distributed data were presented by the
median and the interquartile range. The outcome variables were
graphically described by boxplots. In doing so the natural logarithm
of cytokine release takes into account the wide range of measured
values.
Student’s t-test for two independent samples (abbreviated t-test)
or Mann–Whitney test was applied according to the distribution
of the samples (groups) to be compared. For the analysis of
dependent samples (exposures), Student’s t-test for dependent
samples (abbreviated paired t-test) and the Wilcoxon test were
applied, accordingly. Analysis of variance for repeated measures with
factor A: group; factor B: exposure; and factor A*B: interaction was
carried out.
We tested the null hypothesis that there is no association between
gender and group by applying the w2 test. The null hypothesis that
the age distributions of the groups do not differ was tested using the
Mann–Whitney test. The cutoff level for statistical significance was
taken at 0.05. Several comparisons of the cytokine release of cells
exposed to different substances led to the problem of multiplicity;
however, an adjustment of the cutoff level was not performed, as in
this pilot study any single test is equally important.
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